A Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or II

Clinical trial NCT04208412 · COMPLETED

Trial details

NCT number: NCT04208412
Sponsor: KalVista Pharmaceuticals, Ltd.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Hereditary Angioedema

Start date: 2019-07-02
Primary completion: 2020-12-08
Enrollment: 84

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.